BioPharm International
September 01, 2012
Features
25
9
Michiel E. Ultee of Laureate Biopharmaceutical Services gives an update on 1988 article regarding virus testing and how the advance of monoclonal antibodies has changed processes.
September 01, 2012
Final Word
25
9
Ties between the biotechnology industry and university research are crucial.
September 01, 2012
Boot Camp Business Guide
25
9
Using a competency-based approach to effectively train biopharmaceutical industry staff.
September 01, 2012
Perspectives on Outsourcing
25
9
The weak global economy adds to the challenges of bio/pharma companies and their suppliers.
September 01, 2012
Features
25
9
The authors describe a validation master plan for closed-vial filling technology.
September 01, 2012
Features
25
9
The authors demonstrate how an integrated model is helping to achieve regulatory flexibility. This article is part of a special section on biopharmaceutical trends.
September 01, 2012
Features
25
9
The authors describe a simple method to remove endotoxins from highly viscous formulations.
September 01, 2012
Features
25
9
A perspective on why platform processes are not and should not define the future of bioprocess development efforts. This article is part of a special section on biopharmaceutical trends.
September 01, 2012
Global Reports
25
9
NIH has awarded ten laboratories two-year grants to develop tissue chip technology, with part of the funding coming from the recently established National Center for Advancing Translational Science.
September 01, 2012
Guest Editorial
25
9
PDA's strategic plan calls for maintaining valuable relationships with global regulators.
September 01, 2012
Boot Camp Technical Guide
25
9
NIBRT's Ian Nelligan on what to expect when starting an upstream process, including the choice between single-use and stainless-steel bioreactors.
September 01, 2012
Global Reports
25
9
Brazil's regulatory health authority, Anvisa, plans to establish quality requirements for locally produced pharmaceutical excipients, Anvisa told BioPharm International.
September 01, 2012
Features
25
9
Howard Levine of BioProcess Technology Consultants talks about what industry needs to know to enter the biosimilars game in the US.
September 01, 2012
Regulatory Beat
25
9
Manufacturers and regulators struggle to control phony versions of crucial medicines.